Soleno Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	285.01	190.41	-	-	-	-
Revenue Growth	-	-	-	-	-	-
Cost of Revenue	3.9	2.7	-	-	-	-
Gross Profit	281.11	187.71	-	-	-	-
Selling, General & Admin	153.24	132.13	105.86	13.48	9.84	10.81
Research & Development	38.38	40.63	78.57	25.19	15.27	21.45
Other Operating Expenses	3.05	5.54	3.24	2.71	-0.71	-0.73
Total Operating Expenses	194.68	178.29	187.67	41.38	24.4	31.53
Operating Income	86.44	9.41	-187.67	-41.38	-24.4	-31.53
Interest Income	18.55	16.95	12.05	2.58	0.3	0.11
Interest Expense	-5.41	-5.48	-0.23	-	-	-
Other Non-Operating Income (Expense)	-	-	-	-0.18	0.03	0.51
Total Non-Operating Income (Expense)	13.14	11.48	11.82	2.4	0.33	0.62
Pretax Income	99.58	20.89	-175.85	-38.99	-24.07	-30.91
Provision for Income Taxes	3.54	-	-	-	-	-
Net Income	96.04	20.89	-175.85	-38.99	-24.07	-30.91
Net Income Attributable to Preferred Dividends	0	0.42	-	-	-	-
Net Income to Common	96.04	20.48	-175.85	-38.99	-24.07	-30.91
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	52	51	40	16	8	5
Shares Outstanding (Diluted)	53	52	40	16	8	5
Shares Change	24.73%	30.39%	143.61%	96.40%	57.90%	27.39%
EPS (Basic)	1.82	0.40	-4.38	-2.36	-2.87	-5.81
EPS (Diluted)	1.77	0.39	-4.38	-2.36	-2.87	-5.81
EPS Growth	-	-	-	-	-	-
Shares Outstanding	51.72	52.29	45.7	31.68	8.16	5.32

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	105.42	46.73	-69.31	-24.94	-20.79	-27.79
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	1.98	0.89	-1.73	-1.51	-2.48	-5.23
Gross Margin	98.63%	98.58%	-	-	-	-
Operating Margin	30.33%	4.94%	-	-	-	-
Profit Margin	33.70%	10.97%	-	-	-	-
FCF Margin	36.99%	24.54%	-	-	-	-
EBITDA	88.46	11.43	-185.68	-39.43	-22.43	-29.57
EBITDA Margin	31.04%	6.00%	-	-	-	-
EBIT	86.44	9.41	-187.67	-41.38	-24.4	-31.53
EBIT Margin	30.33%	4.94%	-	-	-	-
Effective Tax Rate	3.55%	0.00%	0.00%	0.00%	0.00%	0.00%

SEC Filings: 10-K · 10-Q